Novel Zika vaccine shows promise in animal models
A potential Zika virus vaccine, developed by deleting part of the Zika genome that codes for the viral shell, was effective and safe in mice.
List view / Grid view
A potential Zika virus vaccine, developed by deleting part of the Zika genome that codes for the viral shell, was effective and safe in mice.
The best protection from COVID-19 will come from intranasally-delivered vaccines, due to the effectiveness of mucosal IgA antibodies, say researchers from the University at Buffalo.
Researchers in the US have developed a potential HIV vaccine approach that aims to prompt the creation of broadly neutralising antibodies via mRNA.
Dr Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles. These nano-size vesicles represent a potentially safe and simple subunit vaccine delivery platform that…
A recently discovered SARS-CoV-2 virus in a Russian bat is likely to be capable of infecting humans and resistant to current vaccines.
In this issue are articles on synthetically engineered bacteria to deliver therapeutics, how single-molecule fluorescence resonance energy transfer was used to image GPCRs and a new assay to identify coronavirus drugs. Also included are pieces on vaccine development, monoclonal antibodies and neuroscience.
References for ‘Advancing vaccines with extracellular vesicles’, in Drug Target Review Issue 3 2022.
Scientists have discovered antibodies that are effective against many different COVID-19 variants.
Vaccinating mice with this universal flu candidate induced broad neuraminidase inhibition, M2 ectodomain specific antibodies and T cell immune responses.
Researchers have developed a safe and versatile platform to increase the thermal stability of vaccines and improve their transportability.
Researchers have designed a COVID-19 vaccine to be less sensitive to mutations and equipped for future strains.
An animal study has shown that a modified vaccine for tuberculosis could treat bladder cancer whilst minimising side effects.
A recent genomic surveillance study has demonstrated the value of genomics to inform vaccine design and highlight the challenge posted by shapeshifting bacteria.
The new RSV vaccine formulation protected newborn mice against infection and evoked strong responses in immune cells from human newborns.
Researchers have developed an mRNA-based cancer vaccine that is delivered directly into the lymphatic system for a more potent response.